Zhejiang Hisun Pharmaceutical Co., Ltd.

XSSC:600267 Stock Report

Market Cap: CN¥9.9b

Zhejiang Hisun Pharmaceutical Past Earnings Performance

Past criteria checks 0/6

Zhejiang Hisun Pharmaceutical's earnings have been declining at an average annual rate of -4.6%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been declining at an average rate of 1% per year.

Key information

-4.6%

Earnings growth rate

-7.1%

EPS growth rate

Pharmaceuticals Industry Growth10.9%
Revenue growth rate-1.0%
Return on equity-0.5%
Net Margin-0.2%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Zhejiang Hisun Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

XSSC:600267 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 249,547-203,037343
30 Jun 249,556-623,026359
31 Mar 2410,036-773,176384
31 Dec 2310,373-933,281392
30 Sep 2311,9946003,436454
30 Jun 2312,3605743,509458
31 Mar 2312,1235863,427442
31 Dec 2212,0374893,422429
30 Sep 2211,7733193,329395
30 Jun 2211,8695263,402394
31 Mar 2212,0464963,443379
31 Dec 2112,1364873,466373
30 Sep 2112,3085743,540403
30 Jun 2112,0404573,499380
31 Mar 2111,9236143,366403
31 Dec 2011,3544173,355401
30 Sep 2010,914-8193,489726
30 Jun 2010,7242813,626892
31 Mar 2010,774-103,903890
31 Dec 1911,072933,923904
30 Sep 1910,6947553,880780
30 Jun 1910,522-4553,630640
31 Mar 1910,163-4723,418641
31 Dec 1810,187-4923,264640
30 Sep 1810,200162,976468
30 Jun 1810,398152,548633
31 Mar 1810,655182,359526
31 Dec 1710,572142,230439
30 Sep 1710,574-1202,155271
30 Jun 1710,509-1012,4240
31 Mar 1710,090-942,3510
31 Dec 169,733-942,3020
30 Sep 169,396402,2570
30 Jun 168,986-32,2320
31 Mar 168,793152,1830
31 Dec 158,767142,1680
30 Sep 159,382852,3030
30 Jun 159,8351752,3520
31 Mar 1510,1452372,4700
31 Dec 1410,0973082,4750
30 Sep 149,6453142,3230
30 Jun 149,1043112,2480
31 Mar 148,8953032,2180
31 Dec 138,6043022,2010

Quality Earnings: 600267 is currently unprofitable.

Growing Profit Margin: 600267 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 600267 is unprofitable, and losses have increased over the past 5 years at a rate of 4.6% per year.

Accelerating Growth: Unable to compare 600267's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 600267 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-2.5%).


Return on Equity

High ROE: 600267 has a negative Return on Equity (-0.53%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies